The information contained in this website has been developed by Arcutis Medical Affairs and is intended for US healthcare professionals (HCPs) only.
Explore a collection of congress presentations and published literature from Arcutis.
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body The ARRECTOR Phase 3 Randomized Clinical Trial
Pooled Safety and Local Tolerability of Roflumilast Cream 0.15% From the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials of Patients With Atopic Dermatitis: Subgroup Analysis of Patients With Prior Inadequate Response, Intolerance, and/or Contraindications to Topical Treatments
Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis: Improvements in Patient-Reported Outcomes (ARRECTOR)
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05%in Pediatric Patients Aged 2–5 Years With Mild-to-ModerateAtopic Dermatitis (INTEGUMENT-PED): A Phase3 Randomized Controlled Trial
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial
Strategies to Increase Patient Diversity in Clinical Trials: Examples From Topical Roflumilast Clinical Development Programs
Patient-Reported Outcomes and Family Impact With Roflumilast Cream in Atopic Dermatitis: Pooled Phase 3 Results
Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema
Once-Daily Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Patients With Diverse Skin Types: Pooled Subgroup Analysis From the Phase 3 INTEGUMENT-1 and -2 Trials
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials
Your file will open automatically upon submission.
Fields marked with an asterisk (*) are required.
Arcutis Biotherapeutics, Inc. (“Arcutis”) understands that protecting your personal information is very important. We do not share any personally identifiable information you give us with third parties for their own marketing purposes.
I would like to receive occasional information from Arcutis about products, services, and opportunities that may be of interest to me and agree to allow Arcutis to use the information provided for this purpose. Examples include, but are not limited to, information or opportunities to participate in surveys or provide feedback, and information about clinical trials.
I can opt out at any time by clicking “Unsubscribe” at the bottom of any such communication, calling 805-418-5006, or by sending a letter to Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361.
For additional details, please see Arcutis’ Privacy Policy.
By clicking Download below, I am agreeing to receive the requested information. I further acknowledge the Arcutis Privacy Policy and affirm that I am at least eighteen (18) years of age.
Δ
You are now leaving the Arcutis Medical Affairs website. Arcutis Biotherapeutics is not responsible for the content on these third-party websites.